DOCSLIB.ORG

Partnerre Trigger Pharmaceuticals (At 2.16.21) Code Brand Name Trade Name Code Brand Name Trade Name J0800 Acthar®

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

PartnerRe Trigger Pharmaceuticals (at 2.16.21) Code Brand Name Trade Name Code Brand Name Trade Name J0800 Acthar® ..................repository corticotropin injection J3590 Danyelza® .......................................... naxitamab-gqgk J9216 Actimmune® .............................interferon gamma-1B J9145 Darzalex Faspro® ................................. daratumumab J9042 Adcetris® ................................... brentuximab vedotin J8999 Daurismo® .................................................... glasdegib J7192 Advate® ........................... factor viii recombinant nos J8499 Demser® ................................................... metyrosine J7207 Adynovate® ...... antihemophilia factor viii, pegylated J1743 Elaprase® ...................................................idursulfase J7210 Afstyla® ....................... recombinant human factor viii J3060 Elelyso® ............................................ taliglucerace alfa J1931 Aldurazyme® .............................................. laronidase J7205 Eloctate®............................. antihemophilic factor viii J8999 Alecensa® ..................................................... alectinib J3590 Elzonris® ...........................................tagraxofusp-erzs J7186 Alphanate® ............. von Willebrand Factor Complex/ J9176 Empliciti® ................................................. elotuzumab antihemophilic J3590 Enspryng® .....................................satralizumab-mwge J7201 Alprolix® ................................... factor ix recombinant J9055 Erbitux® ..................................................... cetuximab J8999 Alunbrig® ..................................................... brigatinib J7192 Esperoct® ......................... factor viii recombinant nos J9302 Arzerra® ................................................. ofatumumab Evkeeza® ......................................... evinacumab-dgnb J1599 Asceniv® ................................... immune globulin-slra J3590 Evrysdi® ....................................................... risdiplam J7196 Atryn® ............................... antithrombin recombinant J1428 Exondys 51® ................................................ eteplirsen J7198 Autoplex T F® ............................ factor ix anti-inhibitor J0180 Fabrazyme® ........................................ agalsidase beta coagulant complex J7198 Feiba NF® .............. anti-inhibitor coagulant complex* J9035 Avastin® ................................................. bevacizumab J1744 Firazyr® ......................................................... icatibant J8999 Ayvakit® ...................................................... avapritinib J8499 Firdapse® .............................................amifampridine C9399 Azedra® ........................................... Iobenguane I 131 J9307 Folotyn® ...................................................pralatrexate J8999 Balversa® ................................................... erdafitinib J8499 Galafold® ....................................................migalastat J9032 Beleodaq® .................................................. belinostat J3590 Gamifant® .......................................emapalumab-izsg J7195 BeneFIX® .................................. factor ix recombinant J1569 Gammagard Liquid®...................IVIG Immune globulin J0597 Berinert® ...............C1 esterase inhibitor concentrate J1566 Gammagard® ........................... IVIG Immune globulin J7599 Blenrep® ........................belantamab mafodotin-blmf J1561 Gammaked® ............................ IVIG Immune globulin J9039 Blincyto® .............................................. blinatomumab J1557 Gammaplex® ........................... IVIG Immune globulin J3590 Breyanzi® ............................ lisocabtagene maraleucel J1561 Gamunex-C® ............................ IVIG Immune globulin J0567 Brineura® ............................................cerliponase alfa J3490 Gattex® .....................................................teduglutide J8999 Brukinsa® ..............................................zanubrubtinib C9056 Givlaari® ....................................................... givosiran J3590 Cablivi® ........................................ caplacizumab-yhdp J0599 Haegarda® ..........C1 esterase inhibitor subcutaneous J8999 Cabometyx® ........................................... cabozantinib J7192 Helixate®.......................... factor viii recombinant nos J8999 Calquence® ............................................ acalabrutinib J7170 Hemlibra® ...................................... emicizumab-kxwh J8499 Carbaglu® ............................................ carglumic acid J1559 Hizentra®/Hizentra 20% .................. immune globulin J1566 Carimune NF® ...... IVIG immune globulin, intravenous subcutaneous, human J8499 Cerdelga® ..................................................... eliglustat J7187 Humate-P® .............. von Willebrand Factor Complex/ J1786 Cerezyme® ..............................................imiglucerase antihemophilic J8499 Chenodal® .................................................. chenodiol J7202 Idelvion® ................................... factor ix recombinant J8499 Cholbam® .................................................. cholic acid J8999 Idhifa® ....................................................... enasidenib J0598 Cinryze® ..................................... C1 esterase inhibitor J0638 Ilaris® ..................................................... canakinumab J7175 Coagadex® .................... coagulation factor X [human] J8999 Imbruvica® .................................................... ibrutinib J7180 Corifact® ................... factor xiii antihemophilic factor Imcivree® .............................................. setmalanotide J0584 Crysvita® .......................................... burosumab-twza J9173 Imfinzi® .................................................... durvalumab J8499 Cuprimine® .............................................penicillamine J8999 Inqovi® ............................decitabine and cedazuridine J9308 Cyramza® ............................................... ramucirumab J8999 Inrebic® ....................................................... fedratinib PartnerRe America Insurance Company PartnerRe Health is a division of PartnerRe Ltd. In the U.S, coverage is underwritten 6900 Wedgwood Road North PartnerRe Health is a division of PartnerRe Ltd. In the U.S, coverage is underwritten SuitePartnerRe 120 American Insurance Company by PartnerRe America Insurance Company. This Literature is descriptive only. Actual Maple Grove, MN 55311 Coverageby PartnerRe is subject America to Insurancethe language Company. of the policies This Literature or agreements is descriptive issued. only. Actual USAPhone +1 415 354 1551 Coverage is subject to the language of the policies or agreements issued. Phonewww.partnerre.com/health +1 612 234 4920 www.partnerre.com/health TRX021621TRX02162 | 21 of0f 33 PartnerRe Trigger Pharmaceuticals (at 2.16.21) Code Brand Name Trade Name Code Brand Name Trade Name J9315 Istodax® .................................................... romidepsin J8499 Orladeyo® ................................................. berotrastat J9280 Jelmyto® ............................... mitomycin/mitomycin-C J8999 Oxlumo® ...................................................... lumasiran J7208 Jivi® .................................. factor viii recombinant nos J3490 Palynziq® ............................................ pegvalise-pqpz J8499 Juxtapid® ....................................................lomitapide J8999 Pemazyre® ................................................ pemigatinib J9354 Kadcyla® ........................ ado-trastuzumab emtansine J9295 Portrazza® ............................................. necitumumab J1290 Kalbitor® ....................................................ecallantide J9204 Poteligeo® ................................mogamulizumab-kpkc J8499 Kalydeco® ..................................................... ivacaftor J1459 Privigen® .................................. IVIG Immune globulin J2840 Kanuma® ............................................. sebelipase alfa J7194 Profilnine® ....................................... factor ix complex J9271 Keytruda® .......................................... pembrolizumab J8999 Qinlock® ....................................................... ripretinib J7190 Koate® ......................................................... factor viii J1301 Radicava® .................................................. edaravone J7192 Kogenate® ....................... factor viii recombinant nos J8499 Ravicti® ................................. glycerol phenylbutyrate J8499 Korlym® .................................................. mifepristone J7203 Rebinyn® ..................... factor ix antihemophilic factor J8499 Koselugo® ................................................. selumetinib J7192 Recombinate® ................. factor viii recombinant nos J7211 Kovaltry® .................... recombinant human factor viii J8999 Retevmo® ................................................selpercatinib J2507 Krystexxa® ................................................ pegloticase J3590 Revcovi® ......................................elapegademase-lvlr Q2042 Kymriah® ........................................... tisagenlecleucel J7178 Riastap® .................. fibrinogen concentrage [human] J9285 Lartruvo® .................................................
Recommended publications
  • Antineoplastic Agents

    Antineoplastic Agents

    bmchp.org | 888-566-0008 wellsense.org | 877-957-1300 Pharmacy Policy Antineoplastic Agents Policy Number: 9.700 Version Number: 2.0 Version Effective Date: 9/1/2021 Product Applicability All Plan+ Products Well Sense Health Plan Boston Medical Center HealthNet Plan New Hampshire Medicaid MassHealth- MCO MassHealth- ACO Qualified Health Plans/ConnectorCare/Employer Choice Direct Senior Care Options Note: Disclaimer and audit information is located at the end of this document. Prior Authorization Policy Products Affected: Daurismo™ (glasdegib tablet) Rubraca™ (rucaparib tablets) Erleada™ (apalutamide tablet) Sarclisa® (Isatuximab–IRFC injection) Farydak® (panobinostat capsule) Tazverik™ (tazemetostat tablet) Folotyn® (pralatrexate injection) Talzenna® (talazoparib capsule) Gleostine™ (lomustine capsule) Tibsovo® (ivosidenib tablet) Idhifa® (enasidenib mesylate tablet) Ukoniq (umbralisib tosylate tablet) Lonsurf® (tipiracil hcl and trifluridine tablet) Valchlor™ (mechlorethamine gel) Lynparza™ (olaparib capsule, and tablets) Zejula™ (niraparib capsules) Ninlaro® (ixazomib capsule) Zelboraf® (vemurafenib tablet) Odomzo® (sonidegib capsules) Zytiga® (abiraterone acetate tablet) Pomalyst® (pomalidomide capsule) + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan. Antineoplastic Agents 1 of 4 The Plan may authorize coverage of the above products for members meeting the following criteria: Covered FDA approved indication Use Use supported by: o American Hospital Formulary Service Drug Information o DRUGDEX Information System o United States Pharmacopeia- Drug Information o National Comprehensive Cancer Network (categories 1,2a, and 2b) Medically accepted indications will also be considered for approval.
  • PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

    PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

    International Journal of Molecular Sciences Review PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects Rosalin Mishra , Hima Patel, Samar Alanazi , Mary Kate Kilroy and Joan T. Garrett * Department of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267-0514, USA; [email protected] (R.M.); [email protected] (H.P.); [email protected] (S.A.); [email protected] (M.K.K.) * Correspondence: [email protected]; Tel.: +1-513-558-0741; Fax: +1-513-558-4372 Abstract: The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted. Keywords: cancer; PIK3CA; resistance; PI3K inhibitors Citation: Mishra, R.; Patel, H.; Alanazi, S.; Kilroy, M.K.; Garrett, J.T.
  • Optumrx Brand Pipeline Forecast

    Optumrx Brand Pipeline Forecast

    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
  • Pharmacokinetics and Exposure-Response Relationship of Teprotumumab Frst 3 Months, Unless Determined to Be Medically Necessary

    Pharmacokinetics and Exposure-Response Relationship of Teprotumumab Frst 3 Months, Unless Determined to Be Medically Necessary

    Clinical Pharmacokinetics https://doi.org/10.1007/s40262-021-01003-3 ORIGINAL RESEARCH ARTICLE Pharmacokinetics and Exposure‑Response Relationship of Teprotumumab, an Insulin‑Like Growth Factor‑1 Receptor‑Blocking Antibody, in Thyroid Eye Disease Yan Xin1 · Fengyan Xu2 · Yuying Gao2 · Nivedita Bhatt1 · Jason Chamberlain1 · Saba Sile1 · Suzy Hammel1 · Robert J. Holt1 · Srini Ramanathan1 Accepted: 10 February 2021 © The Author(s) 2021 Abstract Background and Objective Thyroid eye disease (TED) is characterized by infammation/expansion of orbital tissues, prop- tosis, and diplopia. Teprotumumab is the frst US Food and Drug Administration-approved therapy for TED, administered as an initial intravenous infusion of 10 mg/kg followed by 20 mg/kg every 3 weeks for an additional seven infusions. The objec- tive of this article is to discuss the pharmacokinetics and exposure-response profle for teprotumumab in patients with TED. Methods A population pharmacokinetic analysis was performed to characterize pharmacokinetics and select dosing in patients with TED. Exposure-response was evaluated for efcacy (proptosis response, clinical activity score categorical response, and diplopia response) and safety (hyperglycemia, muscle spasms, and hearing impairment) parameters. Results Teprotumumab pharmacokinetics was linear in patients with TED, with low systemic clearance (0.334 L/day), low volume of distribution (3.9 and 4.2 L for the central and peripheral compartment, respectively), and a long elimination half- life (19.9 days). The approved dosing regimen provided > 20 µg/mL for > 90% insulin-like growth factor 1 receptor saturation throughout the dosing interval. Model-predicted mean (± standard deviation) steady-state area under the concentration-time curve, peak, and trough concentrations in patients with TED were 131 (± 30.9) mg∙h/mL, 643 (± 130) µg/mL, and 157 (± 50.6) µg/mL, respectively.
  • PRIOR AUTHORIZATION CRITERIA for APPROVAL Initial Evaluation Target Agent(S) Will Be Approved When ONE of the Following Is Met: 1

    PRIOR AUTHORIZATION CRITERIA for APPROVAL Initial Evaluation Target Agent(S) Will Be Approved When ONE of the Following Is Met: 1

    Self-Administered Oncology Agents Through Preferred Prior Authorization Program Summary FDA APPROVED INDICATIONS3-104 Please reference individual agent product labeling. CLINICAL RATIONALE For the purposes of the Self -Administered Oncology Agents criteria, indications deemed appropriate are those approved in FDA labeling and/or supported by NCCN Drugs & Biologics compendia with a category 1 or 2A recommendation, AHFS, or DrugDex with level of evidence of 1 or 2A. SAFETY3-104 Agent(s) Contraindication(s) Afinitor/Afinitor Disperz Hypersensitivity to everolimus, to other rapamycin (everolimus) derivatives None Alecensa (alectinib) Alunbrig (brigatinib) None Ayvakit (avapritinib) None Balversa (erdafitinib) None Hypersensitivity to bosutinib Bosulif (bosutinib) Braftovi (encorafenib) None Brukinsa (zanubrutinib) None Cabometyx None (cabozantinib) Calquence None (acalabrutinib) Caprelsa Congenital long QT syndrome (vandetanib) Cometriq None (cabozantinib) Copiktra (duvelisib) None Cotellic (cobimetinib) None Daurismo (glasdegib) None None Erivedge (vismodegib) Erleada (apalutamide) Pregnancy None Farydak (panobinostat) Fotivda (tivozanib) None Gavreto (pralsetinib) None None Gilotrif (afatinib) Gleevec None (imatinib) Hycamtin Severe hypersensitivity to topotecan (topotecan) None Ibrance (palbociclib) KS_PS_SA_Oncology_PA_ProgSum_AR1020_r0821v2 Page 1 of 19 © Copyright Prime Therapeutics LLC. 08/2021 All Rights Reserved Effective: 10/01/2021 Agent(s) Contraindication(s) None Iclusig (ponatinib) Idhifa (enasidenib) None Imbruvica (ibrutinib)
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1

    DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1

    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
  • I4X-JE-JFCM an Open-Label, Multicenter, Phase 1B/2 Study To

    I4X-JE-JFCM an Open-Label, Multicenter, Phase 1B/2 Study To

    Protocol (e) I4X-JE-JFCM An Open-label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC) NCT01763788 Approval Date: 12-Jun-2016 I4X-JE-JFCM(e) Clinical Protocol Page 1 1. Protocol I4X-JE-JFCM(e) An Open-label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC) Confidential Information The information contained in this protocol is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of Necitumumab (IMC-11F8; LY3012211), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. Necitumumab (IMC-11F8; LY3012211) Gemcitabine (LY188011) This is a Phase 1b/2 study in the first-line treatment of patients with advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC).
  • Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria

    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria

    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria HEALTH SYSTEMS DIVISION Prior authorization (PA) criteria for fee-for-service prescriptions for Oregon Health Plan clients March 1, 2021 Contents Contents ................................................................................................................................................................ 2 Introduction........................................................................................................................................................... 7 About this guide ......................................................................................................................................... 7 How to use this guide ................................................................................................................................. 7 Administrative rules and supplemental information .................................................................................. 7 Update information............................................................................................................................................... 8 Effective March 1, 2021 ............................................................................................................................ 8 Substantive updates and new criteria ............................................................................................. 8 Clerical changes ............................................................................................................................
  • IGF System in Sarcomas: a Crucial Pathway with Many Unknowns to Exploit for Therapy

    IGF System in Sarcomas: a Crucial Pathway with Many Unknowns to Exploit for Therapy

    61 1 Journal of Molecular C Mancarella and Targeting IGF system in sarcoma 61:1 T45–T60 Endocrinology K Scotlandi THEMATIC REVIEW 40 YEARS OF IGF1 IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy Caterina Mancarella and Katia Scotlandi Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Orthopaedic Rizzoli Institute, Bologna, Italy Correspondence should be addressed to K Scotlandi: [email protected] This paper forms part of a special section on 40 Years of IGF1. The guest editors for this section were Derek LeRoith and Emily Gallagher. Abstract The insulin-like growth factor (IGF) system has gained substantial interest due to its Key Words involvement in regulating cell proliferation, differentiation and survival during anoikis f sarcomas and after conventional and targeted therapies. However, results from clinical trials have f IGF system been largely disappointing, with only a few but notable exceptions, such as trials targeting f targeted therapy sarcomas, especially Ewing sarcoma. This review highlights key studies focusing on IGF f clinical trials signaling in sarcomas, specifically studies underscoring the properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited. This review discusses the potential roles of IGF2 mRNA-binding proteins (IGF2BPs), discoidin domain receptors (DDRs) and metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) in regulating the IGF system. Deeper investigation of these novel regulators of the IGF system may help us to further elucidate the spatial and temporal control of the IGF Journal of Molecular axis, as understanding the control of this axis is essential for future clinical studies.
  • Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

    Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

    cancers Review Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies Karam Khaddour 1,*, Sushma Jonna 1, Alexander Deneka 2 , Jyoti D. Patel 3, Mohamed E. Abazeed 4, Erica Golemis 2 , Hossein Borghaei 5 and Yanis Boumber 3,6,* 1 Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA; [email protected] 2 Fox Chase Cancer Center, Program in Molecular Therapeutics, Philadelphia, PA 19111, USA; [email protected] (A.D.); [email protected] (E.G.) 3 Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; [email protected] 4 Robert H. Lurie Comprehensive Cancer Center, Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; [email protected] 5 Fox Chase Cancer Center, Department of Hematology and Oncology, Philadelphia, PA 19111, USA; [email protected] 6 Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia * Correspondence: [email protected] (K.K.); [email protected] (Y.B.) Simple Summary: Epidermal growth factor receptor (EGFR) mutations occur in a significant number Citation: Khaddour, K.; Jonna, S.; of lung cancer patients. Treatment outcomes in this subset of patients has greatly improved over the Deneka, A.; Patel, J.D.; Abazeed, M.E.; last decade after the introduction of EGFR tyrosine kinase inhibitors (TKIs), which demonstrated high Golemis, E.; Borghaei, H.; Boumber, Y. efficacy and improved survival in randomized clinical trials. Although EGFR TKIs became the stan- Targeting the Epidermal Growth dard of care in patients with EGFR-mutated lung cancer, resistance almost inevitably develops.
  • Advances in Epidermal Growth Factor Receptor Specific Immunotherapy: Lessons to Be Learned from Armed Antibodies

    Advances in Epidermal Growth Factor Receptor Specific Immunotherapy: Lessons to Be Learned from Armed Antibodies

    www.oncotarget.com Oncotarget, 2020, Vol. 11, (No. 38), pp: 3531-3557 Review Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies Fleury Augustin Nsole Biteghe1,*, Neelakshi Mungra2,*, Nyangone Ekome Toung Chalomie4, Jean De La Croix Ndong5, Jean Engohang-Ndong6, Guillaume Vignaux7, Eden Padayachee8, Krupa Naran2,* and Stefan Barth2,3,* 1Department of Radiation Oncology and Biomedical Sciences, Cedars-Sinai Medical, Los Angeles, CA, USA 2Medical Biotechnology & Immunotherapy Research Unit, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa 3South African Research Chair in Cancer Biotechnology, Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa 4Sun Yat-Sen University, Zhongshan Medical School, Guangzhou, China 5Department of Orthopedic Surgery, New York University School of Medicine, New York, NY, USA 6Department of Biological Sciences, Kent State University at Tuscarawas, New Philadelphia, OH, USA 7Arctic Slope Regional Corporation Federal, Beltsville, MD, USA 8Department of Physiology, University of Kentucky, Lexington, KY, USA *These authors contributed equally to this work Correspondence to: Stefan Barth, email: [email protected] Keywords: epidermal growth factor receptor (EGFR); recombinant immunotoxins (ITs); targeted human cytolytic fusion proteins (hCFPs); recombinant antibody-drug conjugates (rADCs); recombinant antibody photoimmunoconjugates (rAPCs) Received: May 30, 2020 Accepted: August 11, 2020 Published: September 22, 2020 Copyright: © 2020 Biteghe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
  • Interim Report for the First Quarter of 2020

    Interim Report for the First Quarter of 2020

    Genmab Announces Financial Results for the First Quarter of 2020 May 6, 2020; Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2020 Highlights DARZALEX® (daratumumab) net sales increased approximately 49% compared to the first quarter of 2019 to USD 937 million, resulting in royalty income of DKK 775 million DARZALEX approved in Europe in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant U.S. FDA approved TEPEZZA™ (teprotumumab-trbw), developed and commercialized by Horizon Therapeutics, for thyroid eye disease U.S. FDA accepted, with priority review, Novartis’ supplemental Biologics License Application for subcutaneous ofatumumab in relapsing multiple sclerosis Anthony Pagano appointed Chief Financial Officer Anthony Mancini appointed Chief Operating Officer “Despite the unprecedented challenges posed by the coronavirus (COVID-19) pandemic, we will continue to invest in our innovative proprietary products, technologies and capabilities and use our world-class expertise in antibody drug development to create truly differentiated products with the potential to help cancer patients. While Genmab is closely monitoring the developments in the rapidly evolving landscape, we are extremely fortunate to have a solid financial foundation and a fabulous and committed team to carry us through these uncertain times,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Financial Performance First Quarter of 2020 Revenue was DKK 892 million in the first quarter of 2020 compared to DKK 591 million in the first quarter of 2019. The increase of DKK 301 million, or 51%, was mainly driven by higher DARZALEX royalties.